Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26523800 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL26527397 | 0.77 | THRB (0.45) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL6377200 | 0.68 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL26527445 | 0.68 | — | — | |
| SCHEMBL14099430 | 0.68 | POLB (0.39) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL26527407 | 0.67 | NOTUM (0.39) | TSHR | |
| SCHEMBL26523791 | 0.67 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL26527389 | 0.66 | EPHX2 (0.32) | SMN1; SMN2 | |
| SCHEMBL11721070 | 0.65 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 | |
| SCHEMBL26526004 | 0.65 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | SMN1; SMN2 3/4885ALDH1A1 308/4885RAB9A 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.